Skip to main content
. 2016 Aug;7(4):588–594. doi: 10.21037/jgo.2016.05.01

Table 6. Overall survival since diagnosis (upper panel), progression free survival since nab-paclitaxel treatment (middle), overall survival since nab-paclitaxel therapy (lower panel).

Survival rate Days Month
OS (all)
   Mean 659 22
   Median 644.5 21.5
PFS (since nab-paclitaxel)
   Mean 221 7.4
   Median 181 6
OS (since nab-paclitaxel)
   Mean 284 9.5
   Median 270 9

OS, overall survival; PFS, progression free survival.